

John M S Bartlett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2560910/publications.pdf>

Version: 2024-02-01

76
papers

8,901
citations

109137

35
h-index

71532

76
g-index

78
all docs

78
docs citations

78
times ranked

10916
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1656-1664.	3.0	1,505
2	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2105-2122.	0.8	1,362
3	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1364-1382.	1.2	644
4	An International Ki67 Reproducibility Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1897-1906.	3.0	498
5	Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. <i>Clinical Cancer Research</i> , 2018, 24, 1344-1354.	3.2	414
6	Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. <i>Lancet</i> , The, 2011, 377, 321-331.	6.3	346
7	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819.	3.0	319
8	Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 774.	3.4	221
9	An international study to increase concordance in Ki67 scoring. <i>Modern Pathology</i> , 2015, 28, 778-786.	2.9	195
10	Multi-omic machine learning predictor of breast cancer therapy response. <i>Nature</i> , 2022, 601, 623-629.	13.7	187
11	EMT in Breast Carcinoma—A Review. <i>Journal of Clinical Medicine</i> , 2016, 5, 65.	1.0	172
12	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw050.	3.0	166
13	Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 1531-1538.	0.8	160
14	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	5.1	148
15	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
16	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTEMIS): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 656-666.	5.1	114
17	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
18	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. <i>Npj Breast Cancer</i> , 2016, 2, 16014.	2.3	109

#	ARTICLE	IF	CITATIONS
19	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
20	Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 5027-5035.	0.8	90
21	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	2.3	90
22	An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. <i>Modern Pathology</i> , 2019, 32, 59-69.	2.9	78
23	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. <i>Histopathology</i> , 2019, 75, 225-235.	1.6	74
24	Recommendations for Collection and Handling of Specimens From Group Breast Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 5638-5644.	0.8	72
25	Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>European Journal of Cancer</i> , 2017, 82, 219-227.	1.3	71
26	Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) "Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4423-4430.	0.8	66
27	Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts. <i>Journal of Pathology</i> , 2019, 247, 563-573.	2.1	63
28	Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 4477-4484.	0.8	58
29	Predicting Anthracycline Benefit: <i>TOP2A</i> and <i>CEP17</i> Not Only but Also. <i>Journal of Clinical Oncology</i> , 2015, 33, 1680-1687.	0.8	55
30	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-202.	1.3	53
31	Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. <i>PLoS Computational Biology</i> , 2019, 15, e1006596.	1.5	51
32	<i>GSK3β</i> and cyclin D1 expression predicts outcome in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 161-168.	1.1	47
33	ISOWN: accurate somatic mutation identification in the absence of normal tissue controls. <i>Genome Medicine</i> , 2017, 9, 59.	3.6	44
34	Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 262-273.	1.3	43
35	Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 32-40.	1.3	36
36	External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. <i>Journal of Clinical Pathology</i> , 2006, 60, 816-819.	1.0	35

#	ARTICLE	IF	CITATIONS
37	External Quality Assurance of HER2 FISH and ISH Testing. American Journal of Clinical Pathology, 2009, 131, 106-111.	0.4	35
38	How current assay approval policies are leading to unintended imprecision medicine. Lancet Oncology, The, 2020, 21, 1399-1401.	5.1	34
39	Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. Archives of Pathology and Laboratory Medicine, 2016, 140, 66-74.	1.2	33
40	Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Modern Pathology, 2017, 30, 509-518.	2.9	32
41	Pathway-based subnetworks enable cross-disease biomarker discovery. Nature Communications, 2018, 9, 4746.	5.8	30
42	Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles. Artificial Intelligence in Medicine, 2019, 97, 27-37.	3.8	30
43	Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. Journal of Pathology, 2012, 227, 481-489.	2.1	29
44	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper [®] . Breast Cancer Research, 2017, 19, 55.	2.2	29
45	Determination of HER2 Amplification by In Situ Hybridization. American Journal of Clinical Pathology, 2008, 130, 920-926.	0.4	28
46	Biomarkers and Patient Selection for PI3K/Akt/mTOR Targeted Therapies: Current Status and Future Directions. Clinical Breast Cancer, 2010, 10, S86-S95.	1.1	26
47	Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer. Breast Cancer Research, 2016, 18, 16.	2.2	22
48	Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy. European Urology Focus, 2018, 4, 740-748.	1.6	22
49	HER2 status predicts for upfront AI benefit: A [®] TRANS-AIOG meta-analysis of 12,129 patients from A [®] ATAC, BIG 1-98 and TEAM with centrally determined HER2. European Journal of Cancer, 2017, 79, 129-138.	1.3	21
50	A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5462-5476.	3.2	20
51	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. Npj Breast Cancer, 2017, 3, 3.	2.3	17
52	Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance. BMC Cancer, 2014, 14, 762.	1.1	16
53	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. Npj Breast Cancer, 2020, 6, 15.	2.3	16
54	Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study. Journal of Clinical Pathology, 2021, 74, 53-57.	1.0	15

#	ARTICLE	IF	CITATIONS
55	Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies. <i>Scientific Reports</i> , 2016, 6, 29434.	1.6	13
56	Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival. <i>BMC Cancer</i> , 2018, 18, 750.	1.1	13
57	Quantification of Hormone Receptors to Guide Adjuvant Therapy Choice in Early Breast Cancer: Better Methods Required for Improved Utility. <i>Journal of Clinical Oncology</i> , 2011, 29, 3715-3716.	0.8	11
58	Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. <i>Clinical Cancer Research</i> , 2022, 28, 1871-1880.	3.2	11
59	Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 773-781.	1.1	9
60	Incorporation of TILs in daily breast cancer care: how much evidence can we bear?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 147-162.	1.4	9
61	A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon <i>HER2</i> FISH probe: intersite variation can be rigorously controlled using FISH. <i>Histopathology</i> , 2010, 56, 297-304.	1.6	8
62	Multisite verification of the accuracy of a multi-gene next generation sequencing panel for detection of mutations and copy number alterations in solid tumours. <i>PLoS ONE</i> , 2021, 16, e0258188.	1.1	8
63	Virtual tissue microarrays: a novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma <i>in situ</i> . <i>Histopathology</i> , 2014, 65, 2-8.	1.6	7
64	A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials. <i>Oncotarget</i> , 2015, 6, 31693-31701.	0.8	6
65	Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue Samples. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1246-1263.	1.2	5
66	Heterogeneity of Circulating Tumor Cell-Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response. <i>Cancer Research</i> , 2021, 81, 6196-6206.	0.4	5
67	Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. <i>Current Oncology</i> , 2022, 29, 2599-2616.	0.9	5
68	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 98.	2.3	4
69	Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa. <i>Npj Precision Oncology</i> , 2021, 5, 83.	2.3	4
70	Reply to V. Arena et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e9-e10.	0.8	3
71	Expression of activated type I receptor tyrosine kinases in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 701-708.	1.1	3
72	Can immune markers help identify fast relapse in patients with muscle invasive bladder cancer?. <i>Pathology Research and Practice</i> , 2020, 216, 153200.	1.0	2

#	ARTICLE	IF	CITATIONS
73	Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training. PLoS ONE, 2020, 15, e0238593.	1.1	2
74	A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial. Oncotarget, 2016, 7, 49099-49106.	0.8	2
75	Validated or Not Validated? That Is the Question. Journal of the National Cancer Institute, 2014, 106, djt360-djt360.	3.0	0
76	Comparative survival analysis of multiparametric tests when molecular tests disagree A TEAM Pathology study. Npj Breast Cancer, 2021, 7, 90.	2.3	0